CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
(Other OTC:CYDY),(OTC US:CYDY), Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology […]